Brain Metastasis from HER2-Positive Breast Cancer: An Evolving Landscape.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36305867.
- Also identified by DOI 10.1158/1078-0432.CCR-22-2853.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate with ability to cross the blood-tumor barrier and activity on brain metastases. To test the activity of new drugs, patient-derived xenograft models from human brain metastases and phase 0 and window-of-opportunity trials are of utmost importance. See related article by Kabraji et al., p. 174.
Medical subject headings
- Breast Neoplasms
- Immunoconjugates
- Brain Neoplasms